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Abstract
Background: Active efflux systems and reduced cell-wall permeability are considered to be the main causes of
mycobacterial intrinsic resistance to many antimicrobials. In this study, we have compared the Mycobacterium
smegmatis wild-type strain mc
2155 with knockout mutants for porins MspA (the main porin of M. smegmatis) and
MspC, the efflux pump LfrA (the main efflux pump system of M. smegmatis) and its repressor LfrR for their ability
to transport ethidium bromide (EtBr) on a real-time basis. This information was then correlated with minimum
inhibitory concentrations (MICs) of several antibiotics in the presence or absence of the efflux inhibitors
chlorpromazine, thioridazine and verapamil.
Results: In the absence of porins MspA and MspC, accumulation of ethidium bromide decreased and the cells
became more resistant to several antibiotics, whereas the knockout mutant for the LfrA pump showed increased
accumulation of EtBr and increased susceptibility to EtBr, rifampicin, ethambutol and ciprofloxacin. Moreover, the
efflux inhibitors caused a reduction of the MICs of streptomycin, rifampicin, amikacin, ciprofloxacin, clarithromycin
and erythromycin in most of the strains tested.
Conclusions: The methodology used in this study demonstrated that porin MspA plays an important role in the
influx of quaternary ammonium compounds and antibiotics and that efflux via the LfrA pump is involved in low-
level resistance to several antimicrobial drugs in M. smegmatis. The results obtained with this non-pathogenic
mycobacterium will be used in future studies as a model for the evaluation of the activity of the same efflux
inhibitors on the susceptibility of multidrug resistant strains of Mycobacterium tuberculosis to isoniazid and
rifampicin.
Background
The intrinsic resistance of mycobacteria to most antimi-
crobial agents is generally attributed to their relatively
impermeable cell-wall, which provides a barrier to nox-
ious compounds and limits drug uptake [1]. This low
permeability is due to the structure and lipid-rich com-
position of the mycobacterial cell-wall that comprises
long-chain fatty acids, the mycolic acids, covalently
bound to a peptidoglycan-arabinogalactan polymer, and
extractable lipids not covalently linked to the peptido-
glycan-arabinogalactan [1-3]. Diffusion of hydrophilic
nutrients is mediated by pore-forming proteins like the
MspA porin of M. smegmatis, which is described as the
major diffusion pathway for hydrophilic solutes in these
mycobacteria [4,5]. Along with the controlled permeabil-
ity by the cell-wall, active efflux systems can also pro-
vide resistance by extruding noxious compounds prior
to their reaching their intended targets. Intracellular
concentration of a given compound is therefore a result
of interplay between permeability and efflux [6]. In
order to develop effective antimycobacterial therapeutic
strategies at a time when multidrug resistant and exten-
sively drug resistant tuberculosis continue to escalate
[7], the contributions made by alterations of permeabil-
ity due to down regulation of porins and increased
expression of efflux pumps that render these infections
problematic for therapy, must be understood.
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fied and characterized to date [8-14]. However, their role
in intrinsic and acquired drug resistance in mycobacteria
is not completely understood. LfrA, a transporter protein
of the major facilitator superfamily of M. smegmatis,w a s
the first efflux pump to be genetically described in myco-
bacteria and it has been associated with resistance to
ethidium bromide (EtBr), acriflavine, doxorubicin, rhoda-
mine 123 and fluoroquinolones [14-17]. The regulation
of LfrA is controlled by the upstream region of lfrA that
contains a gene coding for LfrR, a putative transcriptional
repressor of the TetR family, which represses the tran-
scription of the lfrRA operon by directly binding to the
promoter region [18,19].
The efflux pump substrate EtBr is widely used as a
probe to detect and quantify efflux activity by bacteria
[20-23]. EtBr emits weak fluorescence in aqueous solu-
tion (outside cells) and becomes strongly fluorescent
when concentrated in the periplasm of Gram-negative
bacteria and in the cytoplasm of Gram-positive bacteria.
As long as EtBr is not intercalated between nucleic bases
of DNA, it is subject to extrusion. When it is intercalated,
the binding constant is sufficiently strong to keep EtBr
from access to the efflux pump system of the bacterium
[24]. Recently, a semi-automated fluorometric method
was developed using EtBr as substrate for the real-time
assessment of efflux pump activity in bacteria [25-27].
The method was developed considering that EtBr accu-
mulation inside the cell is the result of the interplay
between cell-wall permeability and efflux activity. The
fluorescence that results from the overall intracellular
EtBr content is monitored by real-time fluorometry.
In the study to be described, we used this semi-auto-
mated fluorometric method to study EtBr transport in M.
smegmatis, using the wild-type strain mc
2155 and mutant
strains carrying in-frame deletions of genes coding for por-
ins MspA and MspC, the efflux pump LfrA and its repres-
sor LfrR, and correlated this information with the
corresponding antibiotic profile. Since many efflux pumps
of M. smegmatis have their homologues in Mycobacterium
tuberculosis, the use of M. smegmatis as a model
mycobacterium may provide data that will help to under-
stand efflux-mediated drug resistance in M. tuberculosis
and other mycobacteria that infect the human [15].
Results and Discussion
MspA as a major pathway for EtBr in M. smegmatis
The M. smegmatis strains used in this study are described
in Table 1. The accumulation of increasing concentra-
tions of EtBr by strains SMR5, MN01 (ΔmspA)a n d
ML10 (ΔmspAΔmspC) is presented by Figure 1. Accu-
mulation of EtBr under conditions that maximize efflux
(presence of glucose and incubation at 37°C) begins to
take place at a concentration of 1 mg/L in the case of
M. smegmatis SMR5. This concentration of EtBr margin-
ally exceeds the ability of the intrinsic efflux system of
SMR5 to extrude the substrate. In the case of the SMR5
derived porin mutants MN01 (ΔmspA)a n dM L 1 0
(ΔmspA ΔmspC), the marginal concentration that results
in accumulation of EtBr is increased to 2 and 4 mg/L,
respectively (Figure 1) and considered to be the result of
a decreased influx rate of EtBr due to the deletion of por-
ins in these strains [3,5]. These concentrations were
selected to test the effect of the efflux inhibitors chlor-
promazine, thioridazine and verapamil in the accumula-
tion of EtBr by these strains. This is to ensure that the
increase of accumulation of EtBr is due to inhibition of
efflux pumps and not to the use of an EtBr concentration
that the cell’s efflux system cannot extrude. As shown by
Figure 2, the efflux inhibitors chlorpromazine, thiorida-
zine and verapamil, used at ½ the minimum inhibitory
concentration (MIC; see Table 1), increased accumula-
tion of EtBr, although only marginally in strain ML10.
We interpret these results as indicating that because of
the absence of both porins in ML10, little EtBr enters the
cell, accumulation does not take place, and hence, there
is no EtBr subject for extrusion.
LfrA is the main efflux system involved in EtBr extrusion
in M. smegmatis
The accumulation of increasing concentrations of EtBr
by strains mc
2155, XZL1675 (ΔlfrA) and XZL1720
Table 1 Description of M. smegmatis strains used in this study and corresponding MICs determined for EtBr and efflux
inhibitors
M. smegmatis strain Description [Reference] MICs (mg/L)
EtBr CPZ TZ VP
mc
2155 Wild-type [34] 6.25 25 12.5 200
SMR5 mc
2155 derivative; resistant to streptomycin due to a mutation in ribosomal protein S12 (rpsL) [29] 6.25 25 12.5 400
MN01 SMR5 ΔmspA [5] 6.25 25 25 400
ML10 SMR5 ΔmspA ΔmspC [28] 12.5 25 25 250
XZL1675 mc
2155 ΔlfrA [15] 0.4 25 6.25 125
XZL1720 mc
2155 ΔlfrR [15] 6.25 25 12.5 200
CPZ, chlorpromazine; EtBr, ethidium bromide; TZ, thioridazine; VP, verapamil.
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Page 2 of 10(ΔlfrR) is presented by Figure 3. Concerning the knock-
out mutant for the efflux pump LfrA (strain XZL1675),
EtBr started to accumulate at a concentration of
0.25 mg/L. Since in the wild-type strain M. smegmatis
mc
2155, accumulation took place at a concentration of
1 mg/L of EtBr, these results demonstrate an increased
susceptibility of the mutant strain to EtBr due to the
inactivation of efflux pump LfrA. In the case of the lfrR
knockout mutant XZL1720, EtBr accumulation started
at a concentration of 2 mg/L, a higher concentration
than the observed for the wild-type. This could be due
to the constitutive expression of LfrA in this strain as a
consequence of the deletion of its repressor, LfrR. These
results are in agreement to what has been previously
reported regarding LfrA as the main efflux system
involved in EtBr extrusion [15-17]. In order to deter-
mine the effect of the efflux inhibitors chlorpromazine,
thioridazine and verapamil on EtBr efflux activity, efflux
assays were performed for M. smegmatis mc
2155,
XZL1675 and XZL1720. As shown by Figure 4, all
strains presented efflux of EtBr at 37°C in the presence
of glucose. Moreover, this efflux activity was inhibited
by chlorpromazine, thioridazine and verapamil. How-
ever, the concentration of EtBr used for the lfrA mutant
was 15-fold lower than the concentration used for the
wild-type and lfrR deleted strains (0.2 mg/L for
XZL1675 vs 3m g / Lf o rm c
2155 and XZL1720, ½ MIC
for each strain - see Table 1). This further demonstrates
that deletion of lfrA hinders the cell’s ability to efflux
EtBr, resulting in a low MIC for this fluorochrome and
a decreased EtBr efflux activity when compared to
mc
2155 and XZL1720.
Effect of efflux inhibitors on the antibiotic resistance of
M. smegmatis
In order to correlate the data obtained from the
fluorometric method with a drug susceptibility profile,
the MICs of several antibiotics were determined for
each strain (Table 2). Moreover, the effect of the efflux
inhibitors on the reduction of MICs of the same anti-
biotics was also tested (Table 2). M. smegmatis SMR5,
MN01 and ML10 present an MIC for streptomycin
above 256 mg/L due to the presence of a mutation in
the rpsL gene that confers resistance to this antibiotic
[5,28,29]. Deletion of porins MspA (MN01) and MspC
(ML10) caused a decreased susceptibility to clarithro-
mycin, erythromycin and rifampicin. Deletion of lfrA
(XZL1675) increased the susceptibility to ciprofloxacin
and ethambutol (Table 2), which suggests that LfrA
might contribute to the intrinsic resistance of M. smeg-
matis to these drugs, as already reported by other stu-
dies [15]. Moreover, the LfrA mutant also showed
increased susceptibility to EtBr, thioridazine and vera-
pamil (Table 1).
Relatively to the effect of the efflux inhibitors on the
MICs of the tested antibiotics, there is an overall reduc-
tion of the MICs, with the exception of ethambutol, in
all of the studied strains. The fact that the effect of
these inhibitors is not dependent of a given genotype
suggests that these compounds have a wide range of
activity against efflux and are not specific of a particular
efflux pump.
Some of the results obtained in this study are at var-
iance with those reported by others. Firstly, the previous
characterization of the lfrA and lfrR knockout mutant
s t r a i n sb yL ia n dN i k a i d o[ 1 5 ]s h o w e dt h a tt h e r ei sn o
difference between the mutant strains and the wild-type
concerning the MIC for rifampicin (authors reported an
M I Co f1m g / Lf o re a c hs t r a i n ) .I no u rs t u d y ,w e
observed a decrease of the MIC against the lfrA and lfrR
deleted mutants. Secondly, whereas deletion of lfrR is
reported to increase the ciprofloxacin MIC from
0.25 mg/L (wild-type) to 4 mg/L (XZL1720) [15], our
results show that the MIC for ciprofloxacin against the
lfrR mutant is the same observed for the lfrA mutant.
The variance between our results and those of others
may be due to the use of different methods for the
determination of the MICs: microdilution method in
Middlebrook 7H9 medium supplemented with oleic acid
albumin dextrose catalase (OADC) (this study) or
microdilution method in Middlebrook 7H9 medium
supplemented with OADC and Tween 80 in combina-
tion with drug gradient plates [15].
Conclusions
The detection of EtBr influx and efflux can be used to
anticipate transport-mediated antibiotic resistance in
bacteria, since some of these compounds use similar
channels to enter and leave the cell. In this study, we
have compared the wild-type M. smegmatis mc
2155
with knockout mutants for LfrA and MspA for their
ability to transport EtBr. It was observed that in the
a b s e n c eo fM s p A ,t h em a j o rp o r i no fM. smegmatis,
accumulation of EtBr decreased and the mycobacteria
became more resistant to several antibiotics. This is in
accordance with previous studies that demonstrated
MspA as the major diffusion pathway for hydrophilic
solutes in M. smegmatis, mediating the uptake of small
and hydrophilic nutrients such as sugars and phos-
phates across the outer membrane [4,28,30]. Perme-
ability of the cell to EtBr is, in our opinion, dependent
for the most part on the presence of the major porin
MspA. If this were not so, we would then expect little
difference in the accumulation between intact and
MspA deficient strains. This conclusion is supported
by others that demonstrated that deletion of the mspA
gene increased the resistance of M. smegmatis not only
to hydrophilic molecules, but also to hydrophobic
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Page 3 of 10antibiotics, such as erythromycin [31]. However, dele-
tion of mspA causes the alteration in the organisation
of lipids of the mycobacterial outer membrane, result-
ing in a decreased rate of uptake of hydrophobic
agents such as chenodeoxycholate [31,32]. In fact, it
has been previously demonstrated that a M. tuberculo-
sis mutant lacking oxygenated mycolic acids also pre-
sents altered lipid organisation within its outer
membrane, and the permeability to various agents
is also altered [31,32]. Undoubtedly, the lipid
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Figure 1 Accumulation of increasing concentrations of EtBr (0.5-8 mg/L) by M. smegmatis SMR5, MN01 (ΔmspA)a n dM L 1 0
(ΔmspAΔmspC).
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Page 4 of 10organisation and lipid composition of the outer mem-
brane of mycobacteria significantly affects the perme-
ability of agents into the cell.
T h em u t a n tf o rt h eL f r Ap u m ps h o w e di n c r e a s e d
accumulation of EtBr and increased susceptibility to
EtBr, ethambutol and ciprofloxacin. This is in agreement
with other studies that showed that disruption of the
lfrA gene decreased the MIC of EtBr, acriflavine, cipro-
floxacin, doxorubicin and rhodamine [13,16]. Moreover,
it was shown that resistance to the tested antibiotics
MN01
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Figure 2 Effect of efflux inhibitors on the accumulation of EtBr at 1, 2 and 4 mg/L by M. smegmatis SMR5, MN01 (ΔmspA) and ML10
(ΔmspAΔmspC), respectively. CPZ, chlorpromazine; EPI, efflux pump inhibitor; TZ, thioridazine; VP, verapamil.
Rodrigues et al. BMC Microbiology 2011, 11:35
http://www.biomedcentral.com/1471-2180/11/35
Page 5 of 10decreased in the presence of efflux inhibitors in the stu-
died strains, demonstrating that these inhibitors have a
broad range of activity that is not specific to a given
genotype.
In conclusion, the methodology used in this study
demonstrates that porin MspA plays an important role in
the entrance of quaternary ammonium compounds and
antibiotics into the cell. Whether its absence is the main
cause for decreased permeability, or that its absence has
resulted in altered lipid structure of the outer membrane
that is less permeable remains to be elucidated. The same
methodology used to assess permeability also assessed the
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Page 6 of 10activity of the main efflux pump LfrA of the wild-type
strain and of LfrA and LfrR depleted mutants and corre-
lated the degree of activity with low-level resistance to sev-
eral antimicrobial drugs.
The methodology used and the results obtained in this
work will be used in future studies as a working model
for the evaluation of influx and efflux of substrates by
multidrug resistant M. tuberculosis clinical isolates and,
therefore, determine the cause for the multidrug resis-
tant phenotype beyond simple mutation of relevant
targets.
Methods
Materials
EtBr, glucose, phosphate buffered solution (PBS),
chlorpromazine, thioridazine, verapamil, amikacin,
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Figure 4 Efflux of EtBr by M. smegmatis mc
2155, XZL1675 (ΔlfrA) and XZL1720 (ΔlfrR). Efflux takes place at 37°C in the presence of glucose
and is inhibited by the efflux inhibitors thioridazine and verapamil. EtBr was used at ½ MIC for each strain in order to ensure maximum EtBr-
loading of the bacteria, without compromising cellular viability. CPZ, chlorpromazine; EPI, efflux pump inhibitor; TZ, thioridazine; VP, verapamil.
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Page 7 of 10ciprofloxacin, ethambutol, erythromycin, rifampicin
and streptomycin were purchased from Sigma Aldrich
Química SA (Madrid, Spain). Clarithromycin was
obtained from Abbott Laboratories (Abbott Park, IL,
USA). Middlebrook 7H9 broth and OADC supple-
ment were purchased from Difco (Detroit, MI, USA).
All solutions were prepared on the day of the
experiment.
Bacteria
The M. smegmatis strains used in this work are
described in Table 1. M. smegmatis strains SMR5,
MN01 and ML10 were kindly provided by Michael
Niederweis (Department of Microbiology, University of
Alabama at Birmingham, Birmingham, U.S.A); strains
XZL1675 and XZL1720 were kindly provided by Hiroshi
Nikaido (Department of Molecular and Cell Biology,
Table 2 Effect of efflux inhibitors on the MICs of antibiotics for wild-type and mutant strains of M. smegmatis
MICs (mg/L)
M. smegmatis strains
Antibiotic/
EPI
mc
2155
(wild-type)
SMR5
(mc
2155 STR
r)
MN01
(SMR5 ΔmspA)
ML10
(SMR5 ΔmspA ΔmspC)
XZL1675
(mc
2155 ΔlfrA)
XZL1720
(mc
2155 ΔlfrR)
No
EPI
0.5 0.5 0.5 0.5 0.5 0.5
AMK CPZ 0.125 0.125 0.125 0.25 0.063 0.063
TZ 0.063 0.063 0.125 0.25 0.063 0.063
VP 0.125 0.125 0.125 0.25 0.125 0.125
No
EPI
0.25 0.25 0.25 0.25 0.125 0.125
CIP CPZ 0.063 0.063 0.063 0.063 0.063 0.063
TZ 0.063 0.063 0.063 0.063 0.032 0.032
VP 0.063 0.063 0.063 0.063 0.063 0.063
No
EPI
22 8 8 2 2
CLT CPZ 0.25 0.25 0.5 1 0.25 0.25
TZ 0.25 0.25 1 1 0.25 0.25
VP 0.5 0.5 0.5 1 0.5 0.5
No
EPI
1 1 1 1 0.5 1
EMB CPZ 1 1 1 1 0.5 1
TZ 1 1 1 1 0.5 1
VP 1 1 1 1 0.5 1
No
EPI
32 32 64 64 32 32
ERY CPZ 44 8 8 4 4
TZ 4 4 16 16 4 4
VP 88 8 8 8 8
No
EPI
4 4 8 8 0.5 0.5
RIF CPZ 1 1 2 2 0.125 0.125
TZ 2 2 4 4 0.125 0.125
VP 2 2 4 4 0.125 0.25
No
EPI
0.5 >256 >256 >256 0.5 0.5
STR CPZ 0.125 >256 >256 >256 0.032 0.063
TZ 0.125 >256 >256 >256 0.125 0.25
VP 0.25 >256 >256 >256 0.25 0.125
AMK, amikacin; CIP, ciprofloxacin; CLT, clarithromycin; CPZ, chlorpromazine; EMB, ethambutol; EPI, efflux pump inhibitor; ERY, erythromycin; RIF, rifampicin; STR,
streptomycin; TZ, thioridazine; VP, verapamil. Data in bold type represents significant (at least 4-fold) reduction of the MIC produced by the presence of an efflux
inhibitor.
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Mycobacteria were grown at 37°C in Middlebrook 7H9
broth or Middlebrook 7H11 solid medium, supplemen-
ted with 10% (v/v) of OADC.
Determination of Minimum Inhibitory Concentrations
The determination of MICs of EtBr, the efflux inhibitors
chlorpromazine, thioridazine and verapamil and of anti-
biotics studied alone and in the presence of an efflux
inhibitor, was performed by the broth microdilution
method according to the CLSI guidelines [33]. Briefly,
mycobacterial strains were grown at 37°C in Middleb-
rook 7H9 broth supplemented with 10% OADC until an
optical density (O.D.) of 0.8 at a wavelength of 600 nm.
The number of colony-forming units (cfu) correspond-
ing to aliquots of the inoculum was routinely calculated
in order to ensure a constant number of bacterial cells
from experiment to experiment. Bacterial cultures were
diluted in PBS to equal the McFarland No. 0.5 standard
and the final inoculum was prepared by diluting the
bacterial suspension at 1:100. Aliquots of 0.1 mL were
transferred to each well of a 96-well plate that contained
0.1 mL of each compound at concentrations prepared
from 2-fold serial dilutions in 7H9/OADC medium. The
inoculated plates were incubated at 37°C until growth in
the agent-free control-well was evident (2-3 days). The
MIC was defined as the lowest concentration of com-
pound that inhibited visible growth.
Semi-automated fluorometric method
The assessment of accumulation and extrusion of EtBr
on a real-time basis by M. smegmatis strains wild-type
mc
2155, SMR5, porin mutants, MN01 and ML10 and
efflux mutants XZL1675 and XZL1720 (Table 1) was
performed using the semi-automated fluorometric
method, as previously described [25-27].
(i) Accumulation assay
M. smegmatis strains were grown in 5 mL of 7H9/OADC
medium at 37°C until an O.D.600 of 0.8. Cultures were
centrifuged at 13000 rpm for 3 minutes, the supernatant
discarded and the pellet washed in PBS (pH 7.4). The O.
D.600 was adjusted to 0.4 with PBS and glucose was
added at final concentration of 0.4%. Aliquots of 0.095
mL of bacterial suspension were distributed to 0.2 mL
PCR microtubes and EtBr was added at concentrations
that ranged from 0.25 to 8 mg/L. Fluorescence was mea-
sured in the Rotor-Gene™ 3000 (Corbett Research, Syd-
ney, Australia), using the 530 nm band-pass and the 585
nm high-pass filters as the excitation and detection wave-
lengths, respectively. Fluorescence data was acquired
every 60 seconds for 60 minutes at 37°C.
The effect of chlorpromazine, thioridazine and verapa-
mil on the accumulation of EtBr was determined by
adding 0.005 mL of each compound to aliquots of 0.095
mL of EtBr-containing bacterial suspension previously
distributed to 0.2 mL PCR microtubes. Fluorescence was
measured every 60 seconds for 60 minutes at 37°C in
the Rotor-Gene™ 3000. Each inhibitor was used at ½
the MIC in order to not compromise the cellular viabi-
lity (as confirmed by CFUs counting).
(ii) Efflux assay
Mycobacteria were exposed to conditions that promote
maximum accumulation of EtBr: EtBr at ½ MIC for each
strain; no glucose; presence of the efflux inhibitor that
caused maximum accumulation, in this case verapamil;
and incubation at 25°C [25-27]. The EtBr loaded cells were
centrifuged at 13000 rpm for 3 minutes and resuspended
in EtBr-free PBS containing 0.4% glucose. After adjusting
the O.D.600 to 0.4, aliquots of 0.095 mL were transferred to
0.2 mL microtubes. Fluorescence was measured in the
Rotor-Gene™ 3000 as described for the accumulation
assay. Efflux activity was quantified by comparing the
fluorescence data obtained under conditions that promote
efflux (presence of glucose and absence of efflux inhibitor)
with the data from the control in which the mycobacteria
are under conditions of no efflux (presence of an inhibitor
and no energy source). Thus, the relative fluorescence cor-
responds to the ratio of fluorescence that remains per unit
of time, relatively to the EtBr-loaded cells.
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